Full-Time
Posted on 12/8/2025
Advances NAD+ science; consumer products
$120k - $135k/yr
Westwood, CA, USA
Hybrid
Niagen Bioscience focuses on NAD+ science and cellular health, offering Tru Niagen and Niagen Plus consumer products, licensing nicotinamide riboside (NR) to manufacturers, and providing analytical reference standards for research labs. Its flagship ingredient, Niagen, aims to raise cellular NAD+ levels to support mitochondrial function, DNA repair, and metabolism. The company differentiates itself through a 25+-year research history, 35+ human clinical studies, 50+ patents, and partnerships with leading aging biology researchers. Its goal is to extend human healthspan by restoring NAD+ levels and enabling science-based aging interventions across pharma and wellness partnerships.
Company Size
51-200
Company Stage
IPO
Headquarters
Los Angeles, California
Founded
1999
Help us improve and share your feedback! Did you find this helpful?
People at Niagen Bioscience who can refer or advise you
Health Insurance
Wellness Program
Retirement savings with company match
Paid Time Off
Flexible Work Hours
Hybrid Work Options
Niagen Bioscience has partnered with OneSpaWorld to offer pharmaceutical-grade Niagen IV at over 80 medi-spa clinics aboard high-end cruise ships, marking the company's first cruise ship clinic partnership. The collaboration extends Niagen Bioscience's clinical footprint, which already includes over 1,200 healthcare, wellness and longevity clinics across the US. Niagen IV contains pharmaceutical-grade nicotinamide riboside, designed to boost NAD+ levels and support cellular vitality and healthy ageing. The formulation offers 75% shorter infusion times compared to traditional NAD+ IV treatments, with fewer side effects. The partnership introduces a new distribution channel for Niagen Bioscience, targeting health-conscious travellers seeking science-backed wellness experiences. Wells Pharma of Houston will compound and distribute the product to qualified OneSpaWorld locations across the cruise fleet.
Niagen Bioscience remains in focus after Canaccord analyst Susan Anderson lowered the price target from $14 to $13 whilst maintaining a Buy rating, close to the $13.60 fair value estimate. The firm cited strong demand for Niagen's core business following Q4 results and highlighted potential upside from the injectable segment. The company expanded its share buyback programme by $10 million to $20 million total on 19 March 2026. Niagen launched the Skincare Innovation Lab and introduced Niagen NanoCloud, a waterless topical product using its nicotinamide riboside ingredient. Management issued 2026 sales guidance projecting 10% to 15% year-over-year growth, excluding 2025 revenue from its Analytical Reference Standards division, driven by e-commerce and new partnerships.
Niagen Bioscience has launched Niagen Skincare Innovation Lab and introduced Niagen NanoCloud, its first topical skincare product powered by patented nicotinamide riboside. The limited-release product addresses NAD+ degradation in water-based formulations through sealed, waterless sachets that maintain ingredient stability until use. The dermatologist-tested formula combines Niagen with hyaluronic acid, pullulan, squalane and vitamin E. A six-week consumer study of 37 participants showed visible improvements in skin texture, hydration and radiance within two weeks. The launch positions Niagen Bioscience in the global skincare market, valued at $122.11 billion in 2025 and projected to reach $227.13 billion by 2034. Niagen NanoCloud is available on truniagen.com for $59 per 30-sachet unit.
Niagen Bioscience has launched Niagen Skincare Innovation Lab, a product platform translating its NAD+ science into skincare, and debuted Niagen NanoCloud, a limited-release topical product powered by its patented nicotinamide riboside ingredient. The dermatologist-tested product addresses NAD+ degradation in water-based formulations through a sealed, waterless sachet format that preserves potency until use. When mixed with serum or moisturiser, it delivers a precision-dosed treatment containing hyaluronic acid, pullulan, squalane and vitamin E. A consumer study showed visible improvements in skin texture and hydration within two weeks. The launch targets the global skincare market, valued at $122 billion in 2025 and projected to reach $227 billion by 2034. Niagen NanoCloud is available at truniagen.com for $59, containing 30 sachets.
Niagen Bioscience reported 16% year-over-year revenue growth in Q4 2025, reaching $33.8 million, whilst full-year 2025 net revenue grew 30% to $129.4 million. The Nasdaq-listed company ended the year with $64.8 million in cash and no debt. The firm secured a patent for nicotinamide riboside and derivatives in intravenous and injectable formulations, initially launching one SKU targeting the biohacker and longevity communities. CEO Rob Fried said the injections would be priced lower than IV treatments. However, Niagen faces challenges including increased competition in the NAD space and FDA uncertainty around NMN's dietary supplement status. Its No Park Parkinson's study failed to achieve its primary endpoint. The company projects more conservative 10-15% growth for 2026, down from 2025's 30%.